Predicted to enable several functions, including G protein activity; anion binding activity; and protein domain specific binding activity. Predicted to be involved in several processes, including positive regulation of organelle organization; positive regulation of protein phosphorylation; and regulation of defense response. Predicted to act upstream of or within cellular response to type II interferon and response to bacterium. Predicted to be located in several cellular components, including Golgi apparatus; autolysosome; and cytoplasmic vesicle. Predicted to be active in bounding membrane of organelle; endoplasmic reticulum membrane; and mitochondrial membrane. Human ortholog(s) of this gene implicated in inflammatory bowel disease 19 and tuberculosis. Orthologous to human IRGM (immunity related GTPase M); INTERACTS WITH (+)-schisandrin B; 17beta-estradiol; 17beta-estradiol 3-benzoate.
Ifggd3; Ifi1; immunity-related GTPase family M protein; immunity-related GTPase family, M; interferon inducible protein 1; interferon-gamma-inducible GTPase Ifggd3 protein; LOC303090
[dan-shen root extract co-treated with Andrographis paniculata extract] inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of IRGM mRNA], [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of IRGM mRNA
[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRGM1 mRNA, SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRGM1 mRNA]
(+)-JQ1 compound inhibits the reaction [Lipopolysaccharides results in increased expression of IRGM1 mRNA], methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased expression of IRGM1 mRNA]